Challice Lee Bonifant, MD, PhD
Pediatric Cellular Therapy
Highlights
Johns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Challice Lee Bonifant
Primary Academic Title
Assistant Professor of Oncology
Background
Dr. Bonifant is a pediatric oncologist on the blood and marrow transplantation team at the Sidney Kimmel Comprehensive Cancer Center and an Assistant Professor of Pediatric Oncology at the Johns Hopkins University School of Medicine. She is also a member of the Bloomberg-Kimmel Institute for Immunotherapy. Her clinical specialty is stem cell transplantation for high-risk leukemias.
Her research interests are in the areas of immunotherapy of cancer and malignant hematology. Currently, her research focuses on design and development of immune therapies as a treatment for poor-prognosis cancers, including development of engineered cellular immunotherapies for the treatment of Acute Myeloid Leukemia.
Dr. Bonifant is a graduate of Wake Forest University and Georgetown University. She completed her Pediatric and Hematology/Oncology training at Johns Hopkins and at Baylor College of Medicine. Prior to her appointment at Johns Hopkins, she was an Assistant Professor in Pediatrics-Hematology/Oncology at the University of Michigan.
Additional Academic Titles
Assistant Professor of Pediatrics
Research Interests
engineered cellular immunotherapies for the treatment of Acute Myeloid Leukemia, Immunotherapy of cancer, malignant hematology
Selected Publications
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy Oncolytics. 2016; 3:16011.
Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy: The Journal of the American Society of Gene Therapy. 2016; 24(9):1615-26.
Bonifant CL, Velasquez MP, Gottschalk S. Advances in immunotherapy for pediatric acute myeloid leukemia. Expert Opinion on Biological Therapy. 2018; 18(1):51-63.
Krawczyk E, Zolov SN, Huang K, Bonifant CL. T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors. Cancer Immunology Research. 2019; 7(4):683-692.
Zolov SN, Rietberg SP, Bonifant CL. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells. Cytotherapy. 2018; 20(10):1259-1266.
Patents
- Combination CD123 and C-type Lectin Molecule 1 Targeted T cells for Acute Myeloid Leukemia (Co-Inventor), US Provisional Patent Application No. 62/398,859, PCT application US2017/052989
- Chimeric Antigen Receptors Targeting Abnormal Glycobiology (Co-inventor), US Provisional Application No. 62/802,001
- Chimeric Antigen Receptor Comprised of CD123 Binding Domain and IL-7 Intracellular Signaling Domain, US Provisional Patent Application No. 16/644,900, PCT application No. 16/358,253
Honors
2018 Damon Runyon-Jake Wetchler Award for Pediatric Innovation, Damon Runyon Foundation-Jake Wetchler Foundation, 1/1/18
Memberships
- American Academy of Pediatrics
- American Society of Hematology
- American Society of Bone Marrow Transplantation
Locations
- Johns Hopkins Children's Center
- 1800 Orleans Street, Bloomberg 11N, Baltimore, MD 21287
- phone: 410-955-8751
- fax: 410-614-1802
Expertise
Education
Texas Children's Hospital
Fellowship, Pediatric Hematology-Oncology, 2015Johns Hopkins University School of Medicine
Residency, Pediatrics, 2012Georgetown University
Graduate School, PhD, 2009Georgetown University School of Medicine
Medical Education, MD, 2009Board Certifications
Pediatric Hematology-Oncology
American Board of Pediatrics, 2017Pediatrics
American Board of Pediatrics, 2014Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Humana
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- UnitedHealthcare
- Veteran Affairs Community Care Network (Optum-VACCN)